Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Armstrong

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Molecular Cancer Therapeutics|February 16, 2013
Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cellsRuwanthi N Gunawardane, Ronald R Nepomuceno, Allison M Rooks, et al.
The Journal of Clinical Investigation|May 17, 2003
A mechanistic role for cardiac myocyte apoptosis in heart failureDetlef Wencker, Madhulika Chandra, Khanh Nguyen, et al.
The Journal of Biological Chemistry|December 31, 2002
Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAPHua Zou, Ruomei Yang, Junshan Hao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJorge E Cortes, Hagop Kantarjian, James M Foran, et al.
Chemistry & Biology|November 25, 2010
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistryLisa M Wodicka, Pietro Ciceri, Mindy I Davis, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family KinasesGang Liu, Brian T Campbell, Mark W Holladay, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2015
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitorsGang Liu, Sunny Abraham, Xing Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 23, 2003
Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathwayWilliam M Yarbrough, Rupak Mukherjee, G Patricia Escobar, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitorsSunny Abraham, Michael J Hadd, Lan Tran, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Molecular Cancer Therapeutics|February 16, 2013
Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cellsRuwanthi N Gunawardane, Ronald R Nepomuceno, Allison M Rooks, et al.
The Journal of Clinical Investigation|May 17, 2003
A mechanistic role for cardiac myocyte apoptosis in heart failureDetlef Wencker, Madhulika Chandra, Khanh Nguyen, et al.
The Journal of Biological Chemistry|December 31, 2002
Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAPHua Zou, Ruomei Yang, Junshan Hao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJorge E Cortes, Hagop Kantarjian, James M Foran, et al.
Chemistry & Biology|November 25, 2010
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistryLisa M Wodicka, Pietro Ciceri, Mindy I Davis, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family KinasesGang Liu, Brian T Campbell, Mark W Holladay, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2015
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitorsGang Liu, Sunny Abraham, Xing Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 23, 2003
Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathwayWilliam M Yarbrough, Rupak Mukherjee, G Patricia Escobar, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitorsSunny Abraham, Michael J Hadd, Lan Tran, et al.
Pageof 3